FDA Brief

Warning letters Drugs

FDA warning letter to

Macau-Union Pharmaceutical Limited

High riskIssued May 29Posted Jun 9Center for Drug Evaluation and Research (CDER)

Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.

What happened

FDA inspected Macau-Union's drug manufacturing facility from December 15 to 17, 2025, and found significant CGMP violations in finished-product testing, component testing, process and cleaning validation, and stability testing. FDA also reviewed the labels for two Bamboo Pharmacy pain rubs and found them to be unapproved new drugs and misbranded because their claims and natural-herb ingredients did not meet the OTC external analgesic monograph. FDA placed all drugs from the firm on Import Alert 66-40 on March 24, 2026.

What FDA found

  1. FDA says the company released OTC drugs without testing each batch for identity and strength of active ingredients and without adequate microbial testing.

    21 CFR 211.165(a) and 211.165(b)
  2. FDA says the company did not test incoming active ingredients and other components for identity, purity, strength, and quality and did not verify suppliers' certificates of analysis.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. FDA says the company lacked process validation and adequate cleaning procedures for shared equipment and did not have quality control review and approval of production procedures.

    21 CFR 211.100(a)
  4. FDA says the company lacked stability testing to support the labeled expiration dates of its drug products.

    21 CFR 211.137(a)
  5. FDA says the Bamboo Pharmacy Mobility and Relief + Recovery rubs are unapproved new drugs because they do not meet the OTC external analgesic monograph.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  6. FDA says the same rubs are misbranded because they are nonprescription drugs that do not comply with section 505G and lack an approved application.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee); sections 301(a) and 301(d), 21 U.S.C. 331(a) and 331(d)

What FDA wants

Correct violations promptly and respond with detailed corrective action plans, testing and validation documentation, and stability data; FDA also recommends a qualified CGMP consultant and may re-inspect.

Who should pay attention

  • U.S. brands and distributors selling Bamboo Pharmacy or other Macau-Union OTC drugs
  • contract manufacturers and importers of topical OTC drugs
  • quality teams managing supplier qualification and stability programs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk